Subarachnoid Hemorrhage Clinical Trial
Official title:
A Prospective, Multicenter Study to Evaluate the Performance and Safety of the CerebroFlo™ EVD Catheter
The primary goal of this study is to assess the occurrence of flushing interventions to address occlusions during the treatment of interventricular hemorrhage (spontaneous primary IVH or secondary IVH due to ruptured aneurysm).
Status | Recruiting |
Enrollment | 109 |
Est. completion date | December 30, 2024 |
Est. primary completion date | October 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject and/or legally authorized representative has reviewed the IRB- approved consent form, has been properly consented per the protocol and has documented their consent to participate in the study by signing the IRB-approved consent form. 2. Subject is = 18 years of age at the time of consent. 3. Subjects with intraventricular hemorrhage (spontaneous primary IVH or secondary IVH due to ruptured aneurysm) who have had CerebroFlo™ EVD Catheter(s) placed without complication. 4. Subjects who require only one EVD Catheter at initial admission Exclusion Criteria: 1. Subjects with a scalp infection present. 2. Subjects with uncorrectable coagulopathy due to prior administration of anticoagulants at the time the CerebroFlo™ EVD Catheter(s) is placed. 3. Subjects known to have a bleeding diathesis. 4. Subjects in which the CerebroFlo™ EVD Catheter(s) is placed directly into a hematoma 5. Evidence of catheter-associated hemorrhage from insertion of the CerebroFlo EVD Catheter(s) on post-placement CT scan. 6. Subject is pregnant |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Anschutz Medical Campus | Aurora | Colorado |
United States | Our Lady of the Lake Regional Medical Center | Baton Rouge | Louisiana |
United States | Wright State University/Premier Health | Dayton | Ohio |
United States | Loma Linda University Health | Loma Linda | California |
United States | Icahn School of Medicine at Mt. Sinai | New York | New York |
United States | AdventHealth Orlando | Orlando | Florida |
United States | Stanford University | Palo Alto | California |
United States | Medical City Plano | Plano | Texas |
United States | Virginia Commonwealth University Department of Neurosurgery | Richmond | Virginia |
United States | University of Utah Health | Salt Lake City | Utah |
United States | University of Texas Health Science Center | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Integra LifeSciences Corporation |
United States,
Aten Q, Killeffer J, Seaver C, Reier L. Causes, Complications, and Costs Associated with External Ventricular Drainage Catheter Obstruction. World Neurosurg. 2020 Feb;134:501-506. doi: 10.1016/j.wneu.2019.10.105. Epub 2019 Oct 25. — View Citation
Crites L. Reducing Catheter-Related Complications with New Anti-thrombiogenic PICC. JAVA. 2015:20(4):256.
Fargen KM, Hoh BL, Neal D, O'connor T, Rivera-Zengotita M, Murad GJ. The burden and risk factors of ventriculostomy occlusion in a high-volume cerebrovascular practice: results of an ongoing prospective database. J Neurosurg. 2016 Jun;124(6):1805-12. doi: 10.3171/2015.5.JNS15299. Epub 2015 Oct 30. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of flushing interventions to address occlusions | The number of flushing interventions from initial catheter placement through catheter removal, an average of 10 days, to address occlusions. | study device implantation through study device removal | |
Secondary | Change of hemorrhage volume | Change of hemorrhage volume as assessed on pre- and post-insertion of the CerebroFlo device as assessed on CT scan | Device implantation through to 90-Day follow-up | |
Secondary | Assessment of Glasgow Coma Score (GCS) | Assessment of Glasgow Coma Score (GCS) at Admission, Discharge, 30-Day and/or 90-Day timepoints
The Glasgow Coma Scale is divided into three components which are scored separately: ocular response (assessment 1-4 points), motor response (assessment 1-6 points) verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total that will range between a minimum of 3 points (which corresponds to a patient who does not open his eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a patient with open eyes, obeying orders and maintaining a consistent language). It has been considered that the GCS score between 15 and 13 points corresponds to a slight alteration of consciousness, a score of 12-9 points with moderate impairment and 8 points or less with a serious deterioration in level of consciousness. |
Device implantation through to 90-Day follow-up | |
Secondary | Assessment of Modified Rankin Score (mRS) | Assessment of Modified Rankin Score (mRS) at Admission, Discharge, 30-Day and/or 90-Day timepoints
The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 5. Lower scores correlate with less disability/dependence |
Device implantation through to 90-Day follow-up | |
Secondary | Assessment of National Institute of Health Stroke Scale (NIHSS) | Assessment of National Institute of Health Stroke Scale (NIHSS) at Admission, Discharge, 30-Day and/or 90-Day timepoints
NIH Stroke Scale/Score (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. |
Device implantation through to 90-Day follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Recruiting |
NCT04189471 -
Recovery After Cerebral Hemorrhage
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
Recruiting |
NCT02962349 -
TRansfusion Strategies in Acute Brain INjured Patients
|
N/A | |
Completed |
NCT02872857 -
Subarachnoid Hemorrhage Recovery And Galantamine
|
Phase 1/Phase 2 | |
Terminated |
NCT02216513 -
Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
|
Phase 0 | |
Completed |
NCT03164434 -
Influence of Drainage on EVD ICP-signal
|
||
Not yet recruiting |
NCT00905931 -
Lycopene Following Aneurysmal Subarachnoid Haemorrhage
|
Phase 2 | |
Completed |
NCT02389634 -
Identification of Novel Molecular Markers for Vasospasm
|
||
Completed |
NCT01077206 -
High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage
|
Phase 2/Phase 3 | |
Completed |
NCT01261091 -
Early Tracheostomy in Ventilated Stroke Patients
|
N/A | |
Completed |
NCT00962546 -
Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage
|
N/A | |
Completed |
NCT00507104 -
Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
|
||
Completed |
NCT00071565 -
Familial Intracranial Aneurysm Study II
|
N/A | |
Completed |
NCT04052646 -
Prehospital Deaths From Spontaneous Subarachnoid Haemorrhages
|
||
Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
Recruiting |
NCT06033378 -
Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage.
|
N/A | |
Completed |
NCT04308577 -
Diet Induced Ketosis for Brain Injury - A Feasibility Study
|
N/A | |
Recruiting |
NCT06103201 -
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
|
Phase 1 |